Fludrocortisone

證據等級: L5

預測適應症: 8 個

Fludrocortisone: Original Indication Not on File — Assessing Primary Cutaneous T-Cell Lymphoma as a Predicted New Indication

One-Sentence Summary

The evidence pack for Fludrocortisone (DrugBank DB00687) does not contain its original approved indication or mechanism-of-action data — both are flagged as gaps. The TxGNN model’s top-ranked prediction is Primary Cutaneous T-Cell Lymphoma, but this direction is currently supported by 0 clinical trials and only 1 case-report-level publication, and the evidence pack’s own mechanistic analysis flags weak biological plausibility for this specific pairing.

Quick Overview

Item	Content
Original Indication	Not available (no licenses or approved-indication text on file)
Predicted New Indication	Primary Cutaneous T-Cell Lymphoma
TxGNN Prediction Score	99.58%
Evidence Level	L5
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for fludrocortisone is not available in this evidence pack (flagged as a High-severity data gap). Likewise, no original indication is on file, and the drug has zero licenses/approvals recorded in the current market dataset.

That said, the evidence pack’s own mechanistic rationale for this candidate offers relevant context: fludrocortisone acts primarily as a mineralocorticoid receptor agonist, with glucocorticoid activity far weaker than corticosteroids such as prednisone or dexamethasone — the agents actually used for immune modulation and lymphotoxic effect in cutaneous T-cell lymphoma (CTCL). The analysis notes there is no established mechanistic basis for fludrocortisone itself to exert direct anti-tumor or immunomodulatory activity against T-cell lymphoma.

The most plausible explanation offered is that the high TxGNN score reflects a broad “corticosteroid class” edge shared in the knowledge graph between steroid-class drugs and lymphoma-related disease nodes, rather than a drug-specific pharmacological signal for fludrocortisone. This distinction matters: it means the prediction score alone should not be read as evidence of a real biological effect for this specific drug–disease pair.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6028675	1967	Case Report	Archives of Dermatology	“Pathergic granulomatosis” — no abstract available; relevance to CTCL and to fludrocortisone specifically has not been confirmed (title-only reference, Tier 3)

Only one publication is associated with this drug–disease pair, and it is a low-tier case report without an available abstract, so its direct relevance to fludrocortisone’s use in CTCL cannot be confirmed from the evidence on hand.

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug-interaction data were all queried but returned no results — DDI query status: not found; 0 interactions identified.)

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate has no clinical trial evidence, only a single low-quality case report (Tier 3, relevance unconfirmed), and the evidence pack’s own mechanistic review concludes there is no credible pharmacological basis linking fludrocortisone’s mineralocorticoid-dominant activity to a therapeutic effect in Primary Cutaneous T-Cell Lymphoma. The high TxGNN score most likely reflects a shared “corticosteroid class” association in the knowledge graph rather than a drug-specific signal.

To proceed, the following is needed:

TFDA/regulatory label warnings and contraindications (currently a Blocking data gap — required before any S1 safety screening can occur)
Confirmed mechanism-of-action data for fludrocortisone (currently a High-severity gap)
Original approved indication and licensing history, to establish a proper baseline for comparison against the predicted indication
Full-text review of PMID 6028675 to confirm whether it has any genuine relevance to CTCL or fludrocortisone’s use in it
If further exploration of this drug is warranted, the “eye disease” candidate (rank 6, evidence level L4, decision stage S1) shows comparatively stronger — though still indirect — literature support (including a Phase 1 safety trial, PMID 36161841) and may be a more productive research direction than the top-ranked CTCL prediction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.